Quick answers
- What is Erythromycin used for?
- The FDA-approved label (Erythromycin, Dr. Reddy's Labratories Inc., September 25, 2025) says: “Erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Erythromycin have a boxed warning?
- No. None of the 53 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Erythromycin?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Erythromycin been recalled?
- FDA enforcement reports list 2 recalls of products of this medicine; the newest started April 29, 2026 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Erythromycin?
- 33 companies list prescription products of Erythromycin in the FDA NDC Directory, including Arbor Pharmaceuticals, Inc., Bryant Ranch Prepack and Torrent Pharmaceuticals Limited.
What Erythromycin is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. …
— FDA label: Erythromycin, Dr. Reddy's Labratories Inc., effective September 25, 2025. Read the full label on DailyMed →
The FDA has 53 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 53 FDA labels for this medicine have a boxed warning.
Forms and how it is given
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| erythromycin 0.5% ointment | Generic | $2.80–$6.87 per gram 6 packages, lowest to highest |
| erythromycin 2% gel | Generic | $0.6529–$0.6859 per gram 2 packages, lowest to highest |
| erythromycin 20 mg/mL solution | Generic | $0.3641 per mL |
| erythromycin 20 mg/mL swab | Generic | $1.24 per unit |
| erythromycin 250 mg capsule, delayed release pellets | Generic | $5.96 per capsule |
| erythromycin 250 mg tablet, coated | Generic | $1.99 per tablet |
| erythromycin 250 mg tablet, delayed release | Generic | $1.88 per tablet |
| erythromycin 250 mg tablet, film coated | Generic | $1.99 per tablet |
| erythromycin 333 mg tablet, delayed release | Generic | $2.90 per tablet |
| erythromycin 500 mg tablet, coated | Generic | $2.54 per tablet |
| erythromycin 500 mg tablet, delayed release | Generic | $3.33 per tablet |
| erythromycin 500 mg tablet, film coated | Generic | $2.54 per tablet |
NADAC list of November 4, 2026; these prices took effect between April 22, 2026 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Arbor Pharmaceuticals, Inc.6 products
- Bryant Ranch Prepack6 products
- Torrent Pharmaceuticals Limited5 products
- Wilshire Pharmaceuticals5 products
- NuCare Pharmaceuticals, Inc.5 products
- Golden State Medical Supply, Inc.4 products
- Padagis Israel Pharmaceuticals Ltd3 products
- Amneal Pharmaceuticals NY LLC3 products
- Asclemed USA, Inc.3 products
- A-S Medication Solutions3 products
- Modavar Pharmaceuticals LLC2 products
- Proficient Rx LP2 products
- Redpharm Drug2 products
- Ascend Laboratories, LLC2 products
- Orange Pharmaceuticals USA LLC2 products
- Alembic Pharmaceuticals Inc.2 products
- Cadila Pharmaceuticals Limited2 products
- Teva Pharmaceuticals USA, Inc.2 products
- Alembic Pharmaceuticals Limited2 products
- Zydus Pharmaceuticals USA Inc.2 products
- Zydus Lifesciences Limited2 products
- Preferred Pharmaceuticals Inc.1 product
- Sentiss Pharmaceuticals LLC1 product
- Bausch & Lomb Incorporated1 product
- Sportpharm LLC1 product
- St. Mary's Medical Park Pharmacy1 product
- Remedyrepack Inc.1 product
- Cardinal Health 107, LLC1 product
- PD-Rx Pharmaceuticals, Inc.1 product
- Direct_Rx1 product
- Dr. Reddy's Labratories Inc.1 product
- Saptalis Pharmaceuticals, LLC LLC1 product
- Armas Pharmaceuticals Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA050536 ERYC | DR Reddys Labs SA | January 26, 1981 | 23, latest April 23, 2018 2018: Labeling · 2013: Manufacturing (CMC) · 2013: Manufacturing (CMC) |
Generic approvals (18)
- ANDA061621Carnegie · July 11, 1972
- ANDA062298Pharmobedient · March 29, 1982
- ANDA062447Padagis Us · September 26, 1983
- ANDA062746Pharmobedient · December 22, 1986
- ANDA062687Micro Labs · February 5, 1988
- ANDA063038Padagis Us · January 11, 1991
- ANDA063211Padagis Us · January 29, 1993
- ANDA064067Bausch and Lomb Inc · July 29, 1994
- ANDA064126Padagis Us · July 3, 1996
- ANDA064030Sentiss · July 18, 1996
- ANDA210954Amneal Pharms Co · July 2, 2019
- ANDA212015Torrent · July 6, 2020
- ANDA214549Teva Pharms USA Inc · February 11, 2021
- ANDA213628Cadila Pharms Ltd · June 28, 2021
- ANDA211975Torrent · July 26, 2021
- ANDA216066Alkem Labs Ltd · July 13, 2022
- ANDA212693Zydus Lifesciences · March 7, 2023
- ANDA215661Alembic · August 24, 2023
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
April 29, 2026 · Class II · Ongoing · D-0544-2026
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
Erythromycin Tablets, USP, 250 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534; a) 30 count bottles ( — Zydus Pharmaceuticals (USA) Inc
-
April 29, 2026 · Class II · Ongoing · D-0545-2026
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
Erythromycin Tablets, USP, 500 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534; (NDC 70710-1048-3). — Zydus Pharmaceuticals (USA) Inc
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Erythromycin, Dr. Reddy's Labratories Inc., effective September 25, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →